Myelodysplastic Syndrome Drugs Market Expected to Achieve 9.3% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Myelodysplastic Syndrome Drugs Market Size By 2025?
The market for drugs addressing myelodysplastic syndrome has seen a robust growth in recent years. The market, which was valued at $2.25 billion in 2024, is expected to reach $2.44 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.3%. The significant growth observed in the historic period is owed to factors such as the increase in the elderly population, breakthroughs in diagnostic techniques, instances of MDS related to chemotherapy, a rise in cancer survival rates, and progress in clinical studies and medication development.

How Big Is the Myelodysplastic Syndrome Drugs Market Size Expected to Grow by 2029?
The market for myelodysplastic syndrome drugs is predicted to experience significant expansion in the upcoming years, with an expected value of $3.48 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this market growth during the forecast period include an increase in the elderly population, advancements in targeted therapies, an improved understanding of disease processes, enhanced awareness and early diagnosis, and the expansion of oncology research. The market trends to watch during this period include optimization of erythropoiesis-stimulating agents, combined therapy approaches, a growing emphasis on iron chelation therapy, regulatory approvals and market accessibility, and care models that place the patient at the center.

View the full report here:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report

Which Key Market Drivers Powering Myelodysplastic Syndrome Drugs Market Expansion and Growth?
The rise in cases of myelodysplastic syndrome (MDS) is forecasted to boost the expansion of the myelodysplastic syndrome drug market in the forthcoming years. MDS, a collection of disorders marked by unusual growth and maturation of blood cells in the bone marrow, is a form of blood cancer primarily disrupting the creation of healthy blood cells. Drugs designed for MDS treatment work mainly by regulating or suppressing the immune system to reduce the need for red blood cell transfusions. The American Journal of Managed Care, a US magazine, noted in October 2022 that MDS's prevalence in the US is projected to range from 60,000 to 175,000 cases. Consequently, the surge in MDS cases is fueling the growth of the myelodysplastic syndrome drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10675&type=smp

What Are the Key Trends Driving Myelodysplastic Syndrome Drugs Market Growth?
In the market for myelodysplastic syndrome drugs, key businesses are focusing on the production of telomerase inhibitors, which target the enzyme telomerase, to control the disease by restraining the unchecked multiplication of abnormal cells. These inhibitors have been proven to be efficient in this market since they can slow down the rapid growth of these abnormal cells and potentially enhance patient outcomes. In a particular case in June 2024, Geron Corporation, an American biotechnology firm, introduced rytelo (imetelstat), an FDA-endorsed, intravenous telomerase inhibitor for adults with low to intermediate-1 risk myelodysplastic syndromes (LR-MDS) and transfusion dependent anemia who are unresponsive to and ineligible for ESA. Rytelo ensures long-term relief from transfusion, enhances hemoglobin levels, and fills a gap in the myelodysplastic syndrome drugs market, while maintaining a manageable safety profile.

What Are the Emerging Segments in the Myelodysplastic Syndrome Drugs Market?
The myelodysplastic syndrome drugs market covered in this report is segmented -

1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers

Subsegments:
1) By Immunomodulatory Drugs: Thalidomide, Lenalidomide, Pomalidomide
2) By Hypomethylating Agents: Azacitidine, Decitabine, Guadecitabine
3) By Anti-anemics: Erythropoiesis-Stimulating Agents (ESAs), Iron Supplements, Blood Transfusion Products

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10675&type=smp

Who Are the Global Leaders in the Myelodysplastic Syndrome Drugs Market?
Major companies operating in the myelodysplastic syndrome drugs market include Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals plc, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.

Which are the Top Profitable Regional Markets for the Myelodysplastic Syndrome Drugs Industry?
North America was the largest region in the Myelodysplastic syndrome drugs market in 2024.Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10675

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.